Ketamine for the Treatment of Depression in Patients Receiving Hospice Care: A Retrospective Medical Record Review of Thirty-One Cases

Psychosomatics

Volumn 56, Issue 4, 2015, Pages 329-337

  Iglewicz, Alana ^a,b   Morrison, Katherine ^c   Nelesen, Richard A ^a   Zhan, Tingting ^d   Iglewicz, Boris ^e   Fairman, Nathan ^f   Hirst, Jeremy M ^a   Irwin, Scott A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e TEMPLE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; AMINO ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DELUSION; DEPRESSION; DISORIENTATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HOSPICE CARE; HUMAN; INSOMNIA; INTERRATER RELIABILITY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; RETROSPECTIVE STUDY; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; DEPRESSIVE DISORDER; MEDICAL RECORD; MIDDLE AGED; PSYCHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DEPRESSIVE DISORDER; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HOSPICE CARE; HUMANS; KETAMINE; MALE; MEDICAL RECORDS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84937520979     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2014.05.005     Document Type: Article

References (64)

1. Brundtland G.H. From the World Health Organization. Mental health: new understanding, new hope. J Am Med Assoc 2001, 286(19):2391.
2. Carney R.M., Blumenthal J.A., Catellier D., et al. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiol 2003, 92(11):1277-1281.
3. Barth J., Schumacher M., Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004, 66(6):802-813.
4. Carney R.M., Freedland K.E. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol Psychiatry 2003, 54(3):241-247.
5. Satin J.R., Linden W., Phillips M.J. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009, 115(22):5349-5361.
6. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163(1):28-40.
7. Thase M.E., Friedman E.S., Biggs M.M., et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007, 164(5):739-752.
8. Clinical Pharmacology Online. 2008.
9. Matsuo N., Morita T. Physician-reported practice of the use of methylphenidate in Japanese palliative care units. J Pain Symptom Manage 2007, 33(6):655-656.
10. Hardy S.E. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother 2009, 7(1):34-59.
11. Fernandez F., Adams F., Holmes V.F., Levy J.K., Neidhart M. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics 1987, 28(9):455-461.
12. Bruera E., Driver L., Barnes E.A., et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003, 21(23):4439-4443.
13. Wallace A.E., Kofoed L.L., West A.N. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995, 152(6):929-931.
14. Homsi J., Nelson K.A., Sarhill N., et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 2001, 18(6):403-407.
15. Macleod A.D. Methylphenidate in terminal depression. J Pain Symptom Manage 1998, 16(3):193-198.
16. Fernandez F., Levy J.K., Samley H.R., et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med 1995, 25(1):53-67.
17. Lee H., Kim S.W., Kim J.M., Shin I.S., Yang S.J., Yoon J.S. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. Hum Psychopharmacol 2005, 20(2):97-104.
18. Angrist B., d'Hollosy M., Sanfilipo M., et al. Central nervous system stimulants as symptomatic treatments for AIDS-related neuropsychiatric impairment. J Clin Psychopharmacol 1992, 12(4):268-272.
19. Stahl S.M. Stahl's essential psychopharmacology: neuroscientific basis and practical applications 2008, Cambridge University Press, Cambridge; New York. 3rd ed.
20. Krystal J.H. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly 2007, 137(15-16):215-216.
21. Kudoh A., Takahira Y., Katagai H., Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002, 95(1):114-118. [table of contents].
22. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63(8):856-864.
23. Berman R.M., Cappiello A., Anand A., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47(4):351-354.
24. Correll G.E., Futter G.E. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 2006, 7(1):92-95.
25. Liebrenz M., Borgeat A., Leisinger R., Stohler R. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly 2007, 137(15-16):234-236.
26. Liebrenz M., Stohler R., Borgeat A. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry 2009, 10(4pt2):640-643.
27. aan het Rot M., Collins K.A., Murrough J.W., et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010, 67(2):139-145.
28. Phelps L.E., Brutsche N., Moral J.R., Luckenbaugh D.A., Manji H.K., Zarate C.A. Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist. Biol Psychiatry 2009, 65(2):181-184.
29. DiazGranados N., Ibrahim L.A., Brutsche N.E., et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010, 71(12):1605-1611.
30. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009, 66(5):522-526.
31. Larkin G.L., Beautrais A.L. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011, 14(8):1127-1131.
32. Zarate C.A., Brutsche N.E., Ibrahim L., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012, 71(11):939-946.
33. Ibrahim L., Diazgranados N., Franco-Chaves J., et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012, 37(6):1526-1533.
34. Cusin C., Hilton G.Q., Nierenberg A.A., Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry 2012, 169(8):868-869.
35. Murrough J.W., Iosifescu D.V., Chang L.C., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013, 170(10):1134-1142.
36. Murrough J.W., Perez A.M., Pillemer S., et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013, 74(4):250-256.
37. Maeng S., Zarate C.A., Du J., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63(4):349-352.
38. Li N., Lee B., Liu R.J., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329(5994):959-964.
39. Murrough J.W. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther 2012, 91(2):303-309.
40. Wilson K.G., Chochinov H.M., de Faye B.J., Breitbart W. Diagnosis and management of depression in palliative care. Handbook of Psychiatry in Palliative Medicine 2000, 25-50. Oxford University Press, New York. H.M. Chochinov, W. Breitbart (Eds.).
41. National Institutes of Health State-of-the-Science Conference statement: symptom management in cancer: pain, depression, and fatigue 2003; 95(15):1110-1117.
42. Wilson K.G., Chochinov H.M., Skirko M.G., et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage 2007, 33(2):118-129.
43. McDaniel J.S., Brown F.W., Cole S.A. Assessment of depression and grief reactions in the medically ill. Psychiatric Care of the Medical Patient 2000, 149-164. Oxford University Press, New York. 2nd ed. A. Stoudemire, B.S. Fogel, D.B. Greenberg (Eds.).
44. King D.A., Heisel M.J., Lyness J.M. Assessment and psychological treatment of depression in older adults with terminal or life threatening illness. Clin Psychol Sci Pract 2005, 12:339-353.
45. NHPCO's Facts and Figures-Hospice Care in America. National Hospice and Palliative Care Organization. Available from: 2013 [cited 2013]. http://www.nhpco.org/sites/default/files/public/Statistics_Research/2013_Facts_Figures.pdf.
46. Mercadante S., Arcuri E., Ferrera P., Villari P., Mangione S. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 2005, 30(5):485-491.
47. Carr D.B., Goudas L.C., Denman W.T., et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 2004, 108(1-2):17-27.
48. Kannan T.R., Saxena A., Bhatnagar S., Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002, 23(1):60-65.
49. Lauretti G.R., Lima I.C., Reis M.P., Prado W.A., Pereira N.L. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999, 90(6):1528-1533.
50. Mercadante S., Arcuri E., Tirelli W., Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000, 20(4):246-252.
51. Subramaniam K., Subramaniam B., Steinbrook R.A. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004, 99(2):482-495. [table of contents].
52. Lossignol D.A., Obiols-Portis M., Body J.J. Successful use of ketamine for intractable cancer pain. Support Care Cancer 2005, 13(3):188-193.
53. Fitzgibbon E.J., Hall P., Schroder C., Seely J., Viola R. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage 2002, 23(2):165-170.
54. Fine P.G. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage 1999, 17(4):296-300.
55. Clark J.L., Kalan G.E. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage 1995, 10(4):310-314.
56. Irwin S.A., Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med 2010, 13(7):903-908.
57. Irwin S.A., Iglewicz A., Nelesen R.A., et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med 2013, 16(8):958-965.
58. Stefanczyk-Sapieha L., Oneschuk D., Demas M. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. J Palliat Med 2008, 11(9):1268-1271.
59. Guy W: ECDEU Assessment Manual for Psychopharmacology-Revised Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976.
60. Irwin S.A., Pirrello R.D., Hirst J.M., Buckholz G.T., Ferris F.D. Clarifying delirium management: practical, evidenced-based, expert recommendations for clinical practice. J Palliat Med 2013, 16(4):423-435.
61. Goodman L.S., Gilman A., Brunton L.L., Lazo J.S., Parker KL. Goodman & Gilman's the pharmacological basis of therapeutics 2006, McGraw-Hill, New York. 11th ed.
62. Kurul S., Saip P., Aydin T. Totally implantable venous-access ports: local problems and extravasation injury. Lancet Oncol 2002, 3(11):684-692.
63. Monreal M., Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol 2001, 106(1-2):69-72.
64. Sasson M., Shvartzman P. Hypodermoclysis: an alternative infusion technique. Am Fam Physician 2001, 64(9):1575-1578.